Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
- 154 Downloads
Tyrosine kinase inhibitors (TKI) have been demonstrated to prolong survival in patients with chronic myeloid leukemia (CML). However, TKIs may be associated with an increased risk of infections. This study compared healthcare resource utilization (HRU) and costs among patients with CML receiving dasatinib or nilotinib, with a focus on infection-related economic outcomes.
Two large administrative databases were used to identify adult patients newly diagnosed with CML who initiated dasatinib or nilotinib as first- (1L) or second-line (2L) therapy and were classified into the following 1L (dasatinib 1L/nilotinib 1L cohorts) or 2L (dasatinib 2L/nilotinib 2L) cohorts based on the initiated 1L/2L TKI therapy. Infection-related HRU and healthcare costs were compared between cohorts, separately for 1L and 2L.
Cohorts included 1156 patients in the dasatinib 1L and 677 patients in the nilotinib 1L cohorts, 322 patients in the dasatinib 2L, and 207 in the nilotinib 2L cohorts. In 1L and 2L, infection-related HRU was higher for dasatinib than nilotinib cohorts. Infection-related inpatient (IP) days constituted a larger proportion of all-cause IP days in the 1L/2L dasatinib than 1L/2L nilotinib cohorts (dasatinib 1L/2L: 53%/58%; nilotinib 1L/2L: 50%/46%). Compared to the nilotinib cohort, the dasatinib cohort had higher all-cause total costs per patient per year by US$17,901 in 1L and $28,625 in 2L. Of the total cost difference, infection-related were $6048 (34%) in 1L and $28,192 (99%) in 2L, largely driven by IP cost differences (1L/2L: 96%/98%).
Dasatinib was associated with higher HRU and healthcare costs compared to nilotinib, particularly related to infections.
Novartis Pharmaceutical Corporation.
KeywordsChronic myeloid leukemia Costs Dasatinib Infections Healthcare resource utilization Nilotinib Oncology
Sponsorship for this study and article processing charges were funded by Novartis Pharmaceutical Corporation. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Medical Writing, Editorial, and Other Assistance
The authors thank Islam Sadek, an employee of Novartis, for review of the data and scientific input. Medical writing assistance was provided by Sara Kaffashian, an employee of Analysis Group Inc. Analysis Group received consulting fees from Novartis for the conduct of this study.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Karen Seiter has received consulting fees from Novartis as a consultant. Dominick Latremouille-Viau is an employee of Analysis Group, Inc., which has received consultancy fees from Novartis. Annie Guerin is an employee of Analysis Group, Inc., which has received consultancy fees from Novartis. Irina Pivneva is an employee of Analysis Group, Inc., which has received consultancy fees from Novartis. Patrick Gagnon-Sanschagrin is an employee of Analysis Group, Inc., which has received consultancy fees from Novartis. Briana Ndife is an employee of Novartis. Karen Habucky is an employee of Novartis and owns stocks in Novartis and J&J. Derek H. Tang is an employee of Novartis and owns stocks in Novartis. George J. Joseph is an employee of Novartis and owns stocks in Amgen, Pfizer, and Express Scripts.
Compliance with Ethics Guidelines
Data were de-identified to comply with the confidentiality requirements of the Health Insurance Portability and Accountability Act and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Therefore, no institutional review was required.
The claims databases used in this study are proprietary. The authors do not have permission to disseminate the data without the vendor’s approval. The study sponsor has purchased access to the databases and the authors have been granted access to the data on a contract per project use. Access to these datasets are available to any other interested parties for a fee set by the vendor.
- 10.Novartis Pharmaceuticals Canada Inc. TASIGNA® product monograph 2006. https://www.novartis.ca/sites/www.novartis.ca/files/tasigna_scrip_e.pdf. Accessed 6 Jul 2018.
- 11.Bristol-Meyers Squibb. Sprycel (dasatinib) Highlights of Prescribing Information Revised November 2017. https://packageinserts.bms.com/pi/pi_sprycel.pdf. Accessed 6 Jul 2018.
- 12.Al-Ameri AM, Cortes JE, Kantarjian H, Burton E, Quintas-Cardama A, Jabbour E, et al. infectious events in patients with chronic myeloid leukemia treated with nilotinib as a front line therapy and after imatinib failure. Blood. 2010;116(21):1233.Google Scholar
- 24.Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V, et al. Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis. 2011;3(1):e2011021.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States. J Med Econ. 2017;20(1):63–71.CrossRefPubMedGoogle Scholar
- 32.Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Curr Med Res Opin. 2016;32(5):817–27.CrossRefPubMedGoogle Scholar
- 39.Food and Drug Administration. Highlights of prescribing information SPRYCEL® (dasatinib) 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf. Accessed 24 Jul 2018.
- 40.Food and Drug Administration. Highlights of Prescribing Information TASIGNA® (nilotinib) 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf. Accessed 24 Jul 2018.
- 42.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 1.2016. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 15 Mar 2016.